Breakthrough in Ophthalmology: FDA Approves Samsung Bioepis’ Biosimilar Ophthalmic Drug

FDA,Macular,Degeneration,Eylea,Opiforce

Macular degeneration is a severe eye condition that affects millions worldwide, primarily the elderly. This disease deteriorates the central part of the retina, called the macula, leading to vision loss. Eylea (aflibercept) is a leading treatment for macular degeneration, designed to prevent abnormal blood vessel growth in the eye. Developed by Regeneron and Bayer, Eylea’s … 더 읽기

The Future of Mental Health Tracking: How Your Smartphone Keyboard Can Reveal Your Mood

Mental,Health,Relevance,BiAffect,Technology

In an age where technology permeates every aspect of our lives, it’s not surprising that our gadgets can now offer insights into our mental well-being. Recent advancements by researchers at the University of Illinois have led to the development of an innovative app called BiAffect, designed to monitor and interpret the typing patterns on your … 더 읽기

Strategic Moves by HLB BioStep: Enhancing Shareholder Value through Share Repurchase

Strategic,HLB,BioStep,Shareholders,Competencies

HLB BioStep, a subsidiary of HLB Group, recently announced a significant move to acquire treasury shares worth 3 billion KRW (approximately 2.5 million USD). This decision, disclosed on the 21st, is aimed at bolstering shareholder value and reflects the company’s confidence in its growth potential. The share repurchase is part of a broader strategy to … 더 읽기